The functional studies in this paper focused on BRAF, an effector of the growth factor signaling and upstream regulator of the mitogen-activated protein kinase/ERK cascade and a therapeutic target in other cancers such as melanoma [57, 58]. The gene discussed is WNK2; the disease is melanoma.